Vertex Pharmaceuticals Inc. is acquiring Alpine Immune Sciences Inc. for $4.9 billion in cash to gain Alpine’s lead product, phase III-ready povetacicept, which demonstrates best-in-class potential in patients with immunoglobulin A nephropathy (IgAN).
Vifor Pharma and partner Travere Therapeutics on Friday won an endorsement for approval from the European Union's drug regulator for their drug Filspari, part of an industry...
Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.
Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.
Findings from the retrospective cohort study suggest an increased prevalence of advanced kidney disease among individuals with Crohn disease and ulcerative colitis.
Geovanni Faddoul, MD, discusses findings from his recent study examining the impact of induction and maintenance therapy on IgAN recurrence, graft survival, and mortality in kidney transplantation.
Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.
Renal failure risk group classification based on pathological findings from patients’ kidney biopsy, eGFR, and proteinuria was significantly associated with a composite 50% increase in serum creatinine.
Findings suggest serum C3 may be a viable biomarker for the occurrence and prognosis of IgAN, highlighting the role of the complement system in the disease’s pathogenesis.